EA201170028A1 - СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α - Google Patents
СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-αInfo
- Publication number
- EA201170028A1 EA201170028A1 EA201170028A EA201170028A EA201170028A1 EA 201170028 A1 EA201170028 A1 EA 201170028A1 EA 201170028 A EA201170028 A EA 201170028A EA 201170028 A EA201170028 A EA 201170028A EA 201170028 A1 EA201170028 A1 EA 201170028A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tnf
- multispecific
- binding proteins
- target binding
- fusion proteins
- Prior art date
Links
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 abstract 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 abstract 1
- 108050003558 Interleukin-17 Proteins 0.000 abstract 1
- 102000013691 Interleukin-17 Human genes 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 102100021592 Interleukin-7 Human genes 0.000 abstract 1
- 102000014128 RANK Ligand Human genes 0.000 abstract 1
- 108010025832 RANK Ligand Proteins 0.000 abstract 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 abstract 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 abstract 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13409508P | 2008-07-02 | 2008-07-02 | |
| US13409608P | 2008-07-02 | 2008-07-02 | |
| US13409808P | 2008-07-02 | 2008-07-02 | |
| US13409908P | 2008-07-02 | 2008-07-02 | |
| US13409708P | 2008-07-02 | 2008-07-02 | |
| US13410008P | 2008-07-02 | 2008-07-02 | |
| US13410108P | 2008-07-02 | 2008-07-02 | |
| US18009709P | 2009-05-20 | 2009-05-20 | |
| PCT/US2009/049603 WO2010003108A2 (en) | 2008-07-02 | 2009-07-02 | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170028A1 true EA201170028A1 (ru) | 2011-12-30 |
Family
ID=41051379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170028A EA201170028A1 (ru) | 2008-07-02 | 2009-07-02 | СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110152173A1 (enExample) |
| EP (1) | EP2310410A2 (enExample) |
| JP (1) | JP2011526792A (enExample) |
| KR (1) | KR20110044991A (enExample) |
| CN (1) | CN102171247A (enExample) |
| AU (1) | AU2009266863A1 (enExample) |
| BR (1) | BRPI0914005A2 (enExample) |
| CA (1) | CA2729749A1 (enExample) |
| EA (1) | EA201170028A1 (enExample) |
| IL (1) | IL210264A0 (enExample) |
| MX (1) | MX2011000041A (enExample) |
| NZ (1) | NZ590668A (enExample) |
| WO (1) | WO2010003108A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2248899B8 (en) | 2003-03-19 | 2015-07-15 | Biogen MA Inc. | NOGO receptor binding protein |
| EP2474317A1 (en) | 2004-06-24 | 2012-07-11 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
| WO2007008547A2 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| WO2008027986A2 (en) | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| US8632774B2 (en) * | 2008-07-02 | 2014-01-21 | Emergent Product Development Seattle, Llc | Antagonists of IL-6 |
| JP2011527572A (ja) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｌｉｎｇｏ抗体または断片を含む組成物 |
| CN102292352A (zh) * | 2008-10-10 | 2011-12-21 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| WO2011079308A2 (en) * | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| KR101004362B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 |
| KR101004363B1 (ko) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 |
| CA2812430C (en) * | 2010-09-30 | 2019-01-15 | Chengdu Kanghong Biotechnologies Co., Ltd. | Humanized anti-tnf-.alpha. antibody and antigen-binding fragment (fab) thereof and use of the same |
| PT2673373T (pt) * | 2011-02-08 | 2018-12-05 | Medimmune Llc | Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização |
| WO2013065343A1 (ja) | 2011-10-31 | 2013-05-10 | 株式会社 島津製作所 | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| BR112014014418A2 (pt) | 2011-12-15 | 2019-09-24 | Nat Res Council Canada | proteínas de fusão fc de receptor igf solúvel e usos das mesmas |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| PE20142422A1 (es) | 2012-04-05 | 2015-01-21 | Hoffmann La Roche | Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos |
| CN104487587A (zh) | 2012-04-20 | 2015-04-01 | 新兴产品开发西雅图有限公司 | Cd3结合多肽 |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| JP2015518829A (ja) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト |
| CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
| WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| WO2015065987A1 (en) * | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| AU2016205197B2 (en) | 2015-01-08 | 2021-10-21 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| EP3293293A1 (en) * | 2016-09-08 | 2018-03-14 | Italfarmaco SpA | Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α１−アンチキモトリプシンを含むバイオマーカー |
| CA3070272A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| CN119176871A (zh) | 2018-07-24 | 2024-12-24 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌凝集因子a(clfa)的抗体 |
| WO2020076789A2 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| KR102404684B1 (ko) * | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
| US20220242962A1 (en) | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| AU2021207470A1 (en) | 2020-01-13 | 2022-07-07 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
| JP2023548346A (ja) * | 2020-11-11 | 2023-11-16 | ハン，ハック | アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 |
| CN112451670B (zh) * | 2020-11-25 | 2024-01-02 | 沣潮医药科技（上海）有限公司 | 异位内膜治疗的组合物和预后检测试剂盒 |
| KR20230117379A (ko) | 2020-12-01 | 2023-08-08 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 이종이량체 psma 및 cd3-결합 이중특이적 항체 |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| WO2022246244A1 (en) | 2021-05-21 | 2022-11-24 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
| WO2023164898A1 (zh) * | 2022-03-03 | 2023-09-07 | 上海赛金生物医药有限公司 | 一种重组融合蛋白的制剂 |
| WO2023178306A2 (en) * | 2022-03-18 | 2023-09-21 | Fab Biopharma, Inc. | Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus |
| KR20250133692A (ko) | 2023-01-06 | 2025-09-08 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 이중특이성 pd-l1 및 cd40 결합 분자 그리고 이의 용도 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| AU678429B2 (en) * | 1992-12-29 | 1997-05-29 | Genentech Inc. | Treatment of inflammatory bowel disease with IFN-gamma inhibitors |
| US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| AU2507700A (en) * | 1999-01-15 | 2000-08-01 | Biogen, Inc. | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| JP2004537290A (ja) * | 2001-05-24 | 2004-12-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体 |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| DE10148217C1 (de) * | 2001-09-28 | 2003-04-24 | Bosch Gmbh Robert | Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine |
| ES2365606T3 (es) * | 2002-02-13 | 2011-10-07 | Ludwig Institute For Cancer Research Ltd. | Anticuerpos contra gm-csf quiméricos. |
| AU2003256836A1 (en) * | 2002-07-25 | 2004-02-16 | Genentech, Inc. | Taci antibodies and uses thereof |
| KR20120133403A (ko) * | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
| JP2008515970A (ja) * | 2004-10-12 | 2008-05-15 | アンプロテイン コーポレイション | キメラタンパク質 |
| US8420783B2 (en) * | 2004-12-08 | 2013-04-16 | Immunomedics, Inc. | Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| ES2657443T3 (es) * | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| BRPI0610796B8 (pt) * | 2005-05-18 | 2021-05-25 | Morphosys Ag | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| TWI323734B (en) * | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EA017417B1 (ru) * | 2006-02-01 | 2012-12-28 | Сефалон Астралия Пти Лтд. | КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US8632774B2 (en) * | 2008-07-02 | 2014-01-21 | Emergent Product Development Seattle, Llc | Antagonists of IL-6 |
| US20110177070A1 (en) * | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| US20110158995A1 (en) * | 2008-07-28 | 2011-06-30 | Renault S.A.S | Multi-Specific Binding Proteins Targeting B Cell Disorders |
| HRP20180045T1 (hr) * | 2008-10-02 | 2018-03-23 | Aptevo Research And Development Llc | Proteini antagonisti cd86 koji se vežu na više meta |
| CN102292352A (zh) * | 2008-10-10 | 2011-12-21 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
-
2009
- 2009-07-02 US US13/001,087 patent/US20110152173A1/en not_active Abandoned
- 2009-07-02 CN CN2009801338489A patent/CN102171247A/zh active Pending
- 2009-07-02 NZ NZ590668A patent/NZ590668A/xx not_active IP Right Cessation
- 2009-07-02 EA EA201170028A patent/EA201170028A1/ru unknown
- 2009-07-02 MX MX2011000041A patent/MX2011000041A/es not_active Application Discontinuation
- 2009-07-02 BR BRPI0914005A patent/BRPI0914005A2/pt not_active IP Right Cessation
- 2009-07-02 WO PCT/US2009/049603 patent/WO2010003108A2/en not_active Ceased
- 2009-07-02 KR KR1020117002700A patent/KR20110044991A/ko not_active Withdrawn
- 2009-07-02 CA CA2729749A patent/CA2729749A1/en not_active Abandoned
- 2009-07-02 JP JP2011516886A patent/JP2011526792A/ja active Pending
- 2009-07-02 AU AU2009266863A patent/AU2009266863A1/en not_active Abandoned
- 2009-07-02 EP EP09774557A patent/EP2310410A2/en not_active Withdrawn
-
2010
- 2010-12-26 IL IL210264A patent/IL210264A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011000041A (es) | 2011-05-23 |
| KR20110044991A (ko) | 2011-05-03 |
| WO2010003108A3 (en) | 2010-02-25 |
| WO2010003108A2 (en) | 2010-01-07 |
| CA2729749A1 (en) | 2010-01-07 |
| AU2009266863A1 (en) | 2010-01-07 |
| US20110152173A1 (en) | 2011-06-23 |
| BRPI0914005A2 (pt) | 2015-11-17 |
| NZ590668A (en) | 2012-12-21 |
| JP2011526792A (ja) | 2011-10-20 |
| IL210264A0 (en) | 2011-03-31 |
| CN102171247A (zh) | 2011-08-31 |
| EP2310410A2 (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170028A1 (ru) | СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α | |
| NZ592420A (en) | Cd86 antagonist multi-target binding proteins | |
| EA201170031A1 (ru) | СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ ПО ОТНОШЕНИЮ К TGF-β | |
| EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| MX388059B (es) | Composiciones y metodos para modular la comunicacion celular. | |
| EA201001223A1 (ru) | Стабилизированные белковые композиции | |
| ATE464908T1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
| EA201692543A1 (ru) | Антагонисты активина-actriia и их применение для стимулирования роста кости | |
| EA201170636A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| EA201001139A1 (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB | |
| EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
| EA201290254A1 (ru) | Антагонисты il-17a | |
| EA201491186A1 (ru) | Полипептиды химерного фактора viii и их применение | |
| WO2021127200A8 (en) | Ilt3-binding agents and methods of use thereof | |
| WO2007071448A3 (en) | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation | |
| CO6280541A2 (es) | Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40 | |
| DK1966244T3 (da) | Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130 | |
| WO2014144573A3 (en) | Multimerization technologies | |
| MX2007010349A (es) | Composiciones y metodos para clasificar muestras biologicas. | |
| EA201491107A1 (ru) | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3 | |
| WO2010142551A3 (en) | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family | |
| IS2786B (is) | Prótín sem bindast viðtaka Nogo | |
| EA201491120A1 (ru) | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3 |